Journal Mobile Options
Table of Contents
Vol. 71, Suppl. 1, 2009
Issue release date: January 2009
Horm Res 2009;71:52–56

Turner Syndrome 2008

Bondy C.A.
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Fetuses with prenatal diagnoses of 45,X Turner syndrome (TS) and abnormal fetal ultrasounds have poor prognoses for survival, but with modern medical management, those that do survive to birth may have good clinical outcomes. Fetuses with incidental diagnoses of mosaicism for 45,X associated with normal ultrasounds have a high survival rate and may have no or only mild features of TS. Current Guidelines: At present, appropriate treatment for girls with TS may include growth-promoting therapy and pubertal induction with the dual aims of optimizing adult height and facilitating psychosocial adjustment. Current recommendations advocate mimicking normal physiology as much as possible, with use of microdose estradiol to initiate puberty. Healthcare providers should play a role in helping girls psychosocially adapt to ovarian failure. We now recognize there is an unacceptably high rate of premature mortality in adults with TS, mainly because of complications from congenital heart disease. Cardiac magnetic resonance imaging is recommended to screen for individuals at high risk for serious complications.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Stochholm K, Juul S, Juel K, Naeraa RW, Hojbjerg Gravholt C: Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006;91:3897–3902.
  2. Ross J, Roeltgen D, Zinn A: Cognition and the sex chromosomes: studies in Turner syndrome. Horm Res 2006;65:47–56.
  3. Matura LA, Ho VB, Rosing DR, Bondy CA: Aortic dilatation and dissection in Turner syndrome. Circulation 2007;116:1663–1670.
  4. Ho VB, Bakalov VK, Cooley M, Van PL, Hood MN, Burklow TR, Bondy CA: Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation 2004;110:1694–1700.
  5. Gravholt CH, Landin-Wilhelmsen K, Stochholm K, Hjerrild BE, Ledet T, Djurhuus CB, Sylven L, Baandrup U, Kristensen BO, Christiansen JS: Clinical and epidemiological description of aortic dissection in Turner’s syndrome. Cardiol Young 2006;16:430–436.
  6. Gravholt CH, Juul S, Naeraa RW, Hansen J: Prenatal and postnatal prevalence of Turner’s syndrome: a registry study. BMJ 1996;312:16–21.
  7. Huang B, Thangavelu M, Bhatt S, Sandlin CJ, Wang S: Prenatal diagnosis of 45,X and 45,X mosaicism: the need for thorough cytogenetic and clinical evaluations. Prenat Diagn 2002;22:105–110.
  8. Robinson A, Bender B, Linden M: Decisions following the intrauterine diagnosis of sex chromosome aneuploidy. Am J Med Genet 1989;34:552–554.
  9. Koeberl DD, McGillivray B, Sybert VP: Prenatal diagnosis of 45,X/46,XX mosaicism and 45,X: implications for postnatal outcome. Am J Hum Genet 1995;57:661–666.
  10. Gunther DF, Eugster E, Zagar AJ, Bryant CG, Davenport ML, Quigley CA: Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life. Pediatrics 2004;114:640–644.
  11. The Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–3366.
  12. Carel J-C: Growth hormone in Turner syndrome: twenty years after, what can we tell our patients? J Clin Endocrinol Metab 2005;90:3793–3794.
  13. Bolar K, Hoffman AR, Maneatis T, Lippe B: Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab 2008;93:344–351.
  14. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA: Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406–3416.
  15. Opitz JM, Pallister PD: Brief historical note: the concept of ‘gonadal dysgenesis.’ Am J Med Genet 1979;4:333–343.
  16. Bondy CA: Care of girls and women with Turner syndrome: a guideline of the Turner syndrome study group. J Clin Endocrinol Metab 2007;92:10–25.
  17. Hanton L, Axelrod L, Bakalov V, Bondy CA: The importance of estrogen replacement in young women with Turner syndrome. J Womens Health (Larchmt) 2003;12:971–977.
  18. Sachdev V, Matura LA, Sidenko S, Ho VB, Arai AE, Rosing DR, Bondy CA: Aortic valve disease in Turner syndrome. J Am Coll Cardiol 2008;51:1904–1909.
  19. Loscalzo ML, Van PL, Ho VB, Bakalov VK, Rosing DR, Malone CA, Dietz HC, Bondy CA: Association between fetal lymphedema and congenital cardiovascular defects in Turner syndrome. Pediatrics 2005;115:732–735.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50